We believe that the importance of BiP as biomarker lies on its early detection, before the development of the hyperinflammatory response, when IL-6 is elevated, so patients with one of the pulmonary risk factors found in this study (for example EPOC) can be tested with this biomarker to assess the possibility of having a prophylactic treatment (for example 4-PBA) before developing pneumonia. This evidence concerns the gene IL6 and susceptibility to pneumonia measurement.